Biotinylated SARS-CoV-2 Spike RBD Beta Variant

<strong>Biotinylated SARS-CoV-2 Spike RBD Beta Variant </strong>_x000D_ <strong>Catalog number:</strong> B2010503_x000D_ <strong>Lot number:</strong> Batch Dependent_x000D_ <strong>Expiration Date:</strong> Batch dependent_x000D_ <strong>Amount:</strong> 25 ug_x000D_ <strong>Molecular Weight or Concentration:</strong> 27 kDa_x000D_ <strong>Supplied as:</strong> Liquid Solution_x000D_ <strong>Applications:</strong> molecular component of many serological and antigenic assays for SARS-CoV-2 and its variants_x000D_ <strong>Storage:</strong> -20℃_x000D_ <strong>Keywords:</strong> Beta Variant Spike, B.1.351 Spike RBD, Beta RBD, Biotin Beta RBD_x000D_ <strong>Grade:</strong> Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity &gt;18 MΩ-cm) and are filtered through 0.22 um._x000D_ _x000D_ <a href="https://moleculardepot.com/wp-content/uploads/2022/03/MKT-010-SARS-CoV-2-Brochure-Rev-A.pdf"><strong>Download SARS-CoV-2 Brochure</strong></a>_x000D_ _x000D_ <strong>References:</strong>_x000D_ 1: Aleem A, Akbar Samad AB, Slenker AK. Emerging Variants of SARS-CoV-2 And_x000D_ Novel Therapeutics Against Coronavirus (COVID-19). 2021 Jul 18. In: StatPearls_x000D_ [Internet]. Treasure Island (FL): StatPearls Publishing; 2021 Jan–._x000D_ _x000D_ 2: Binette V, Côté S, Haddad M, Nguyen PT, Bélanger S, Bourgault S, Ramassamy C,_x000D_ Gaudreault R, Mousseau N. Corilagin and 1,3,6-Tri-<i>O</i>-galloy-β-D-glucose:_x000D_ potential inhibitors of SARS-CoV-2 variants. Phys Chem Chem Phys. 2021 Jul_x000D_ 14;23(27):14873-14888._x000D_ _x000D_ 3: Kim Y, Gaudreault NN, Meekins DA, Perera KD, Bold D, Trujillo JD, Morozov I,_x000D_ McDowell CD, Chang KO, Richt JA. Effects of Spike Mutations in SARS-CoV-2_x000D_ Variants of Concern on Human or Animal ACE2-Mediated Virus Entry and_x000D_ Neutralization. bioRxiv [Preprint]. 2021 Aug 25:2021.08.25.457627._x000D_ _x000D_ 4: Jin D, Wei J, Sun J. Analysis of the molecular mechanism of SARS-CoV-2_x000D_ antibodies. Biochem Biophys Res Commun. 2021 Aug 20;566:45-52._x000D_ _x000D_ 5: Jette CA, Cohen AA, Gnanapragasam PNP, Muecksch F, Lee YE, Huey-Tubman KE,_x000D_ Schmidt F, Hatziioannou T, Bieniasz PD, Nussenzweig MC, West AP, Keeffe JR,_x000D_ Bjorkman PJ, Barnes CO. Broad cross-reactivity across sarbecoviruses exhibited_x000D_ by a subset of COVID-19 donor-derived neutralizing antibodies. bioRxiv_x000D_ [Preprint]. 2021 Apr 26:2021.04.23.441195._x000D_ _x000D_ 6: Malladi SK, Patel UR, Rajmani RS, Singh R, Pandey S, Kumar S, Khaleeq S, van_x000D_ Vuren PJ, Riddell S, Goldie S, Gayathri S, Chakraborty D, Kalita P, Pramanick I,_x000D_ Agarwal N, Reddy P, Girish N, Upadhyaya A, Khan MS, Kanjo K, Bhat M, Mani S,_x000D_ Bhattacharyya S, Siddiqui S, Tyagi A, Jha S, Pandey R, Tripathi S, Dutta S,_x000D_ McAuley AJ, Singanallur NB, Vasan SS, Ringe RP, Varadarajan R. Immunogenicity_x000D_ and Protective Efficacy of a Highly Thermotolerant, Trimeric SARS-CoV-2 Receptor_x000D_ Binding Domain Derivative. ACS Infect Dis. 2021 Aug 13;7(8):2546-2564._x000D_ _x000D_ 7: Chen L, Zody MC, Di Germanio C, Martinelli R, Mediavilla JR, Cunningham MH,_x000D_ Composto K, Chow KF, Kordalewska M, Corvelo A, Oschwald DM, Fennessey S,_x000D_ Zetkulic M, Dar S, Kramer Y, Mathema B, Germer S, Stone M, Simmons G, Busch MP,_x000D_ Maniatis T, Perlin DS, Kreiswirth BN. Emergence of Multiple SARS-CoV-2 Antibody_x000D_ Escape Variants in an Immunocompromised Host Undergoing Convalescent Plasma_x000D_ Treatment. mSphere. 2021 Aug 25;6(4):e0048021._x000D_ _x000D_ 8: Tian F, Tong B, Sun L, Shi S, Zheng B, Wang Z, Dong X, Zheng P. N501Y_x000D_ mutation of spike protein in SARS-CoV-2 strengthens its binding to receptor_x000D_ ACE2. Elife. 2021 Aug 20;10:e69091._x000D_ _x000D_ 9: Makdasi E, Zvi A, Alcalay R, Noy-Porat T, Peretz E, Mechaly A, Levy Y,_x000D_ Epstein E, Chitlaru T, Tennenhouse A, Aftalion M, Gur D, Paran N, Tamir H,_x000D_ Zimhony O, Weiss S, Mandelboim M, Mendelson E, Zuckerman N, Nemet I, Kliker L,_x000D_ Yitzhaki S, Shapira SC, Israely T, Fleishman SJ, Mazor O, Rosenfeld R. The_x000D_ neutralization potency of anti-SARS-CoV-2 therapeutic human monoclonal_x000D_ antibodies is retained against viral variants. Cell Rep. 2021 Aug 21:109679._x000D_ <a href="https://pubmed.ncbi.nlm.nih.gov/34329818/">10: Lee YG, Kang KW, Hong W, Kim YH, Oh JT, Park DW, Ko M, Bai YF, Seo YJ, Lee_x000D_ SM, Kim H, Kang SC. Potent antiviral activity of Agrimonia pilosa, Galla rhois,_x000D_ and their components against SARS-CoV-2. Bioorg Med Chem. 2021 Sep 1;45:116329.</a>_x000D_ _x000D_ <strong>Products Related to Biotinylated SARS-CoV-2 Spike RBD Beta Variant </strong> <a href="https://moleculardepot.com/product-category/SARS-CoV-2/">: SARS-CoV-2</a>